OTCMKTS:EVTCY - Evotec Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
+0.30 (1.20%)

This chart shows the closing price for EVTCY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evotec Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVTCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVTCY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Evotec in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $89.50.

This chart shows the closing price for EVTCY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Evotec. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/11/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
4/22/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
3/5/2021CitigroupDowngradeBuy ➝ Neutral
1/28/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
1/19/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
11/20/2020Royal Bank of CanadaReiterated RatingOutperform
9/10/2020Royal Bank of CanadaInitiated CoverageOutperform
9/1/2020CitigroupInitiated CoverageBuy
3/12/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
8/21/2019Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
4/10/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
7/27/2018Deutsche Bank AktiengesellschaftReiterated RatingBuy
11/8/2017DZ BankReiterated RatingSell
8/17/2017DZ BankReiterated RatingSell
8/10/2017DZ BankReiterated RatingSell
7/31/2017DZ BankReiterated RatingSell
7/25/2017Roth CapitalReiterated RatingBuy
7/12/2017DZ BankReiterated RatingSell
6/6/2017Berenberg BankDowngradeBuy ➝ Hold
5/20/2017Berenberg BankReiterated RatingBuy
5/11/2017Berenberg BankReiterated RatingBuy$85.00 ➝ $80.00
5/10/2017Berenberg BankReiterated RatingBuy
5/3/2017Deutsche Bank AktiengesellschaftReiterated RatingNeutral
4/3/2017Deutsche Bank AktiengesellschaftReiterated RatingNeutral
3/31/2017DZ BankReiterated RatingSell
3/31/2017Deutsche Bank AktiengesellschaftReiterated RatingNeutral
3/30/2017DZ BankReiterated RatingSell
2/17/2017DZ BankReiterated RatingNeutral
2/10/2017DZ BankReiterated RatingNeutral
1/10/2017DZ BankReiterated RatingNeutral
12/9/2016DZ BankReiterated RatingBuy
11/18/2016Deutsche Bank AktiengesellschaftReiterated RatingNeutral
10/25/2016DZ BankReiterated RatingBuy
7/11/2016DZ BankReiterated RatingBuy
(Data available from 6/21/2016 forward)
Evotec logo
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE has a strategic collaboration with the University Hospital Erlangen regarding molecular analyses of biospecimens from the German chronic kidney disease cohort study. The company was founded in 1993 and is headquartered in Hamburg, Germany.
Read More

Today's Range

Now: $89.50
Low: $89.50
High: $89.50

50 Day Range

MA: $82.88
Low: $76.44
High: $89.50

52 Week Range

Now: $89.50
Low: $51.35
High: $90.14



Average Volume

781 shs

Market Capitalization

$7.36 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Evotec?

The following Wall Street sell-side analysts have issued reports on Evotec in the last twelve months: Citigroup Inc., Deutsche Bank Aktiengesellschaft, Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for EVTCY.

What is the current price target for Evotec?

0 Wall Street analysts have set twelve-month price targets for Evotec in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Evotec in the next year.
View the latest price targets for EVTCY.

What is the current consensus analyst rating for Evotec?

Evotec currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EVTCY, but not buy more shares or sell existing shares.
View the latest ratings for EVTCY.

What other companies compete with Evotec?

How do I contact Evotec's investor relations team?

Evotec's physical mailing address is Manfred Eigen Campus Essener Bogen 7, Hamburg 2M, 22419. The company's listed phone number is (494) 056-0810 and its investor relations email address is [email protected] The official website for Evotec is www.evotec.com.